• Cash position $2.9m
• R&D tax refund for 2017 expected in quarter ending June 2018
Melbourne, Australia, 30 April 2018: Sienna Cancer Diagnostics Ltd (ASX:SDX) (“Sienna” or “The Company”), a medical technology company developing and commercialising innovative cancer- related tests, is pleased to release its Appendix 4C – Quarterly Cash Flow Report for the quarter ended 31 March 2018.
The Company ended the quarter with a cash balance of $2.9 million. Product orders were received in each month of the quarter. An inter-bank communication problem prevented the receipt of funds for our US distributor’s (StatLab) January order during the quarter. The issue was resolved and the funds were received in early April. Payments for the February and March orders are due to be received in the quarter ending 30 June 2018.
To view Report please download PDF attached:
Download this document
